Shares of Indoco Remedies Ltd. experienced a significant rebound, climbing 7% in Thursday's trade following news that a critical inspection of its Goa manufacturing facility by the UK Medicines and Healthcare products Regulatory Agency (UK-MHRA) concluded with no adverse findings.
The company's stock opened at Rs 233.65 and quickly rose to Rs 248.30, marking a 7.39% increase from its previous close of Rs 231.20. This surge provided much-needed relief to investors after the stock had seen a 16% decline over the preceding five sessions, from September 3 to September 9, 2026.
UK-MHRA Inspection Details
The UK-MHRA conducted its inspection of Indoco Remedies' Plant I facility in Goa between September 7 and September 9, 2026. This facility is responsible for manufacturing solid oral dosage forms and is crucial for the company's exports to various regulated markets globally.
The current Good Manufacturing Practices (cGMP) inspection concluded with a clean report, indicating no critical or major observations. This outcome reaffirms the plant's adherence to stringent quality and regulatory standards, which are vital for pharmaceutical production.
Commitment to Quality and Compliance
Commenting on the successful audit, Indoco Remedies Managing Director Aditi Panandikar stated, "The successful completion of the UKMHRA cGMP inspection with no critical or major observations is a strong validation of our robust quality systems."
The company emphasized its ongoing commitment to maintaining high standards of quality and regulatory compliance across all its operations. Plant I in Goa is not only approved by the UK-MHRA but also holds approvals from other leading global regulatory bodies, including the US Food and Drug Administration (US FDA), Australia's Therapeutic Goods Administration (TGA), and the Malta Medicines Authority. Furthermore, the facility boasts World Health Organization (WHO) Good Manufacturing Practices approval.
Indoco Remedies' Global Footprint
Indoco Remedies is a research-oriented pharmaceutical company with a significant global presence. The company operates ten manufacturing facilities, six dedicated to finished dosage forms and four for active pharmaceutical ingredients (APIs). Additionally, it maintains a robust R&D center and a contract research organization (CRO) facility, reinforcing its capabilities in drug development and manufacturing for regulated markets such as the UK, Europe, South Africa, New Zealand, Australia, and Canada.